Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Banz

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 5, 2005
Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technologyKurt Banz,
Vaccine|August 30, 2008
Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised casesPaolo Bonanni, Sara Boccalini, Angela Bechini, et al.
Health Policy (Amsterdam, Netherlands)|July 26, 2014
Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal productsBjörn Schwander, Kurt Banz, Klaus Kaier, et al.
Health Economics Review|July 11, 2015
Exploratory cost-effectiveness analysis of cardiac resynchronization therapy with systematic device optimization vs. standard (non-systematic) optimization: a multinational economic evaluationKurt Banz, Peter Paul Delnoy, Jean Renaud Billuart
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
The burden of varicella in Germany. Potential risks and economic impactKurt Banz, Stefan Wagenpfeil, Albrecht Neiss, et al.
Medical Microbiology and Immunology|November 1, 2002
Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in GermanyPeter Wutzler, Albrecht Neiss, Kurt Banz, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 25, 2003
Validation of health economic models: the example of EVITAThomas Hammerschmidt, Anita Goertz, Stefan Wagenpfeil, et al.
Human Vaccines|October 16, 2009
Economic evaluation of varicella vaccination in Swiss children and adolescentsKurt Banz, Andrea Iseli, Christoph Aebi, et al.
Human Vaccines|October 16, 2009
Prospective surveillance of varicella-zoster virus infections in an out-patient setting in SwitzerlandAndrea Iseli, Christoph Aebi, Kurt Banz, et al.
Journal of Medical Economics|January 30, 2013
Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findingsRebecca L Hancock-Howard, Christopher M Feindel, Josep Rodes-Cabau, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 5, 2005
Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technologyKurt Banz,
Vaccine|August 30, 2008
Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised casesPaolo Bonanni, Sara Boccalini, Angela Bechini, et al.
Health Policy (Amsterdam, Netherlands)|July 26, 2014
Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal productsBjörn Schwander, Kurt Banz, Klaus Kaier, et al.
Health Economics Review|July 11, 2015
Exploratory cost-effectiveness analysis of cardiac resynchronization therapy with systematic device optimization vs. standard (non-systematic) optimization: a multinational economic evaluationKurt Banz, Peter Paul Delnoy, Jean Renaud Billuart
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
The burden of varicella in Germany. Potential risks and economic impactKurt Banz, Stefan Wagenpfeil, Albrecht Neiss, et al.
Medical Microbiology and Immunology|November 1, 2002
Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in GermanyPeter Wutzler, Albrecht Neiss, Kurt Banz, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 25, 2003
Validation of health economic models: the example of EVITAThomas Hammerschmidt, Anita Goertz, Stefan Wagenpfeil, et al.
Human Vaccines|October 16, 2009
Economic evaluation of varicella vaccination in Swiss children and adolescentsKurt Banz, Andrea Iseli, Christoph Aebi, et al.
Human Vaccines|October 16, 2009
Prospective surveillance of varicella-zoster virus infections in an out-patient setting in SwitzerlandAndrea Iseli, Christoph Aebi, Kurt Banz, et al.
Journal of Medical Economics|January 30, 2013
Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findingsRebecca L Hancock-Howard, Christopher M Feindel, Josep Rodes-Cabau, et al.
Pageof 2